Oncology Center, St. Augustinus Hospital, Oosterveldlaan 24, 2610 Wilrijk-Antwerp, Belgium.
Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.
Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that angiogenesis, and VEGF in particular, could be inhibited without the risk of major side effects. After the pivotal data in first-line studies in patients with colorectal cancer, numerous clinical trials have been undertaken in patients with breast cancer. This review attempts to update these investigations and define the role of anti-VEGF antibody treatment in advanced breast cancer.
大量的临床前和临床证据使血管生成成为癌症的特征之一。在许多人类肿瘤中，血管内皮生长因子（VEGF）已被确定为这一过程的关键介质。最初的研究表明，血管生成，特别是 VEGF，可以被抑制，而不会有产生重大副作用的风险。在一线治疗结直肠癌患者的关键数据公布后，在乳腺癌患者中进行了许多临床试验。本文试图更新这些研究结果，并确定抗 VEGF 抗体治疗在晚期乳腺癌中的作用。
